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Purpose: Pericytes play a specialized role in regulating angiogenesis and vascular function by providing vascular stability
and controlling endothelial cell proliferation. Disorders in pericyte function and pericyte-endothelial interaction have been
observed in several disease states including tumor angiogenesis and diabetic microangiopathy. In ischemic retinal disease,
hypoxia is a potent driver of retinal angiogenesis. This study investigated the effects of hypoxia on retinal pericyte gene
expression, and demonstrates a role in angiogenesis regulation for the hypoxia driven gene, chordin-like 1 (CHL-1).
Methods: In the current studies, we investigated hypoxia-induced gene expression in human retinal pericytes and found
that expression of CHL-1, a member of the bone morphogenetic protein (BMP) superfamily, is upregulated by hypoxia.
We investigated regulation of CHL-1 expression and the ability of CHL-1 to antagonize the antiangiogenic properties of
BMP-4 using a human cell-based angiogenesis assay.
Results: We report that hypoxia induced hypoxia inducible factor-1α-driven expression of CHL-1. Both CHL-1 and
BMP-4 were secreted from human retinal pericytes. We found that CHL-1 complexes with BMP-4 to antagonize the
antiangiogenic  effects  of  BMP-4,  and  that  BMP-4  and  vascular  endothelial  growth  factor  (VEGF)  co-regulate
angiogenesis.
Conclusions: We propose that hypoxia-induced upregulation of CHL-1 alters the homeostatic balance between BMP-4
and VEGF to synergize with VEGF in driving retinal angiogenesis.
Diabetic retinopathy is a microvascular complication of
both Type 1 and Type 2 diabetes and is characterized by
increased  tissue  ischemia,  angiogenesis,  and  permeability.
This microvascular disease is a major cause of blindness in
the working age population [1]. The development of diabetic
retinopathy reflects the convergence of hemodynamic and
metabolic  insults,  including  hyperglycemia,  in  susceptible
individuals.
Vascular endothelial growth factor (VEGF) is known to
be induced by hypoxia and may mediate hypoxia-induced
angiogenesis [2]. VEGF alone is sufficient to produce many
of the vascular abnormalities common to diabetic retinopathy
and other ischemic retinopathies, such as hemorrhage, edema,
venous  beading,  capillary  occlusion  with  ischemia,
microaneurysm  formation,  and  intraretinal  vascular
proliferation [3].
Retinal  pericytes  are  smooth  muscle-like  cells  with
attenuated  processes  enveloping  the  abluminal  surface  of
microvessels  and  sharing  a  common  basement  membrane
with the underlying endothelium (reviewed in [4]). Pericytes
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express  alpha-smooth  muscle  actin  and  have  thus  been
implicated  to  have  a  contractile  function  [5].  They  are
proposed  to  regulate  microvascular  angiogenesis  and
synthesize components of the vascular basement membrane
[6,7]. Pericytes have been demonstrated to be involved in the
regulation of endothelial cell number and morphology and
microvessel architecture [8].
In this study we present novel findings that chordin-like
1 (CHL-1), a bone morphogenetic protein (BMP) antagonist
[9], is upregulated by hypoxia in human retinal pericytes, and
that its expression is driven by hypoxia inducible factor-1α
(HIF-1α).  CHL-1  has  previously  been  reported  to  be
expressed in the developing retina [9], but has not yet been
associated with diabetic or ischemic retinopathy. BMP-4 has
been implicated in angiogenesis through a VEGF-dependent
mechanism [10]. We therefore propose that CHL-1 expression
by human retinal pericytes in response to hypoxia may play
an important role in regulating retinal angiogenesis through
modulation of BMP-4 actions on endothelial cells.
METHODS
Cell culture and hypoxia: Primary cultures of human retinal
pericytes (hRPC) were obtained from Cambrex (Nottingham,
UK) and were cultured in MCDB131 medium (Invitrogen,
Paisley, Scotland) supplemented with 2 mM L-glutamine 50
U/ml penicillin, 50 μg/ml streptomycin, and 10% (v/v) fetal
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1138bovine serum. For experiments, cells were used at passage
four or less and maintained in medium with 10% serum. HeLa
(LGC promochem, Teddington, UK) cells were cultured in
minimum  essential  medium  (Sigma,  Dublin,  Ireland)
supplemented with 10% (v/v) fetal bovine serum, 2 mM L-
glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, and
non-essential amino acids (Sigma). Cos7 (LGC Promochem)
cells were cultured in DMEM (Cambrex) supplemented with
10% (v/v) fetal bovine serum, 2 mM L-glutamine, 50 U/ml
penicillin, and 50 μg/ml streptomycin.
For hypoxia experiments, cells were placed in an hypoxia
chamber (Coy Laboratories, Grass Lake, MI) allowing the
establishment of humidified, ambient, atmospheric hypoxia
of 1% O2 with 5% CO2 and a balance of N2. Temperature was
maintained at 37 °C. Extracellular pO2 measurements were
made  by  using  fluorescence  quenching  oxymetry
(Oxylite-2000; Oxford Optronix, Oxford, UK).
RNA extraction and cDNA synthesis:  RNA was extracted
from  hRPC  using  RNeasy  kit  (Qiagen,  Crawley,  UK)
according to the manufacturer’s instructions. RT–PCR was
performed as follows: 2 μg of total RNA was treated with
DNaseI  (Invitrogen),  according  to  the  manufacturer’s
instructions,  to  remove  chromosomal  DNA.  Reverse
transcription  was  performed  using  random  primer
(Invitrogen)  and  Superscript  II  (Invitrogen)  using  the
manufacturer’s protocol.
Limited cycle PCR was performed using the following
primers, designed using the Primer3 software described in
(Table 1) [11].
Real-time (Taqman) polymerase chain reaction: Real-time
(Taqman) polymerase chain reaction transcript levels were
determined  by  real-time  PCR  using  a  PerkinElmer  7700
analyzer (Perkin Elmer Life Sciences, Shelton, CT). Probe
and primer sequences were described in Table 1. Probes were
labeled with 5′-FAM and 3′-TAMRA as quencher with the
exception of the ribosomal probe, which was labeled with 5′-
VIC to facilitate multiplexing. All results were normalized to
18S rRNA (pre-developed assay reagent, PerkinElmer Life
Sciences).
Gene microarray analysis: RNA isolation was performed as
described in the previous section. In vitro transcription and
microarray analysis were performed as follows: 5 μg of total
RNA were annealed to 100 pmol of the T7-(dT)24 primer.
Then  first-strand  cDNA  synthesis  was  completed  by
incubating the mixture with 1 μl of Superscript II RT (200
units) at 42 °C for 1 h. Second-strand synthesis was performed
in a total volume of 150 μl. Following purification, the cDNA
was  extracted  with  phenol  chloroform,  precipitated  with
ammonium acetate, and resuspended in RNase-free water.
Synthesis of cRNA was performed by in vitro transcription.
The  amplified  cRNA  was  purified  with  an  affinity  resin
column.  Biotin-labeled  cRNA  prepared  from  template
cDNAs was fragmented and hybridized to the HG U133A
array (Affymetrix, High Wycombe, UK). Arrays were then
washed and fluorescently labeled before being scanned using
a  confocal  scanner.  Microarray  Suite  5.1  software
(Affymetrix) was used to analyze the relative abundance of
each  gene  from  the  average  difference  of  fluorescent
intensities. Calculated signal/log ratios for each gene at all
TABLE 1. LIMITED CYCLE AND REAL TIME PCR PRIMERS
Limited cycle PCR primers
Gene Sense primer 5′-3′ Antisense primer 5′-3′ Probe 5′-3′
VEGF CTGCTCTACCTCCACCATGC CTGCATTCACATTTGTTGTGC
CHL-1 TCTGTCACCTTTTGCAGTGG GTTGCCGATTCTGAA AGAGC
Cox2 AACAGGAGCATCCTGAATGG ATTTCATCTGCCTGCTCTGG
RTP801 TCTTAGCAGTTCTCGCTGACC TGGCACACAAGTGTTCATCC
BMP-2 CAAGATGAACACAGCTGG TTTGCTGTACTAGCGACACC
BMP-4 GGCTGTCAAGAATCATGG GCTCAGGATACTCAAGAC
18S GTGGAGCGATTTGTCTGGTT CGCTGAGCCAGTCAGTGTAG
Real time PCR primers
Gene Sense primer 5′-3′ Antisense primer 5′-3′ Probe 5′-3′
VEGF GTGCCCACTGAGGAGTCCA GTGCTGGCCTTGGTGAGGT CATCACCATGCAGATTATGCGGATCAA
Cox2 AGCCCTTCCTCCTGTGCCT CAGGAAGCTGCTTTTTACC TGATTGCCCGACTCCCTTG
CHL-1 CGTAGCTGAAGGGCTCTTT ACACGTTTCCCTCCGAACA AAATCGGCAACCCAATCAAT
Limited cycle PCR was performed using primers, designed using Primer3   software [11]. For real-time, PCR probes were labeled
with 5′-FAM and 3′-TAMRA as quencher with the exception of the ribosomal probe, which was labeled with 5′-VIC to facilitate
multiplexing.
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1139time points of hypoxia were compared to normoxia, and those
genes with a value greater than 0.6 or less than –0.6 (1.5 fold
difference) in all three biologic replicate experiments were
examined further.
Cloning of the chordin-like 1 promoter and open reading
frame:  A  1537  bp  fragment  of  the  CHL-1  promoter  was
amplified using the Advantage2 PCR enzyme system (BD
Biosciences, Oxford, UK) from a human genomic library
EMBL3  SP6/T7  (HL  1067  J,  BD  Biosciences)  with  the
following  primers,  sense  5′-GGA  GAT  AAC  AAC  CAG
AGA GTA GTG G-3′ and, antisense 5′-GAA AAG GAG
GTG AGG GAA GC-3′. The PCR product was immediately
cloned into the TA cloning vector pCRII-TOPO (Invitrogen).
The plasmid was restricted using the enzymes Kpn1 (NEB)
and  Xho1  (NEB),  the  resulting  promoter  fragment  was
subcloned  into  the  reporter  vector  pGL3  Basic  (Promega
Southampton, UK).
The open reading frame of CHL-1 was amplified using
the Advantage2 PCR enzyme system (BD Biosciences) using
human retinal pericyte cDNA as a template. A sense primer
with a BamH1 site, 5′-GCT CGG ATC CGC CTG TCA CCT
TTT GCA GTG GTC-3′, and an antisense primer with an
EcoR1 site, 5′-TGC AGA ATT CGC TTA CAG TGG CCC
TTT TCA GAT C-3′, were used to generate CHL-1 expression
from  a  parent  vector,  pcDNA6/V5-His  C  (Invitrogen),
designated pcDNA6 CHL-1/V5-His.
Overexpression of hypoxia inducible factor-1α: Wild-type
(WT) and double mutant (DM) constructs expressing HIF-1α
were a gift from Thilo Hagen (University College London,
London, UK). Prolines 564 and 402 were mutated to alanine,
as these are the residues important for targeted degradation in
normoxia  [12].  Pericytes  were  transfected,  according  to
manufacturer’s protocol, with 4 µg of each construct using 12
µl Fugene 6 (Roche, Dublin, Ireland). After 24 h following
transfection, the medium was changed and the cells were
incubated for a further 24 h. RNA was then isolated and
analyzed  by  RT–PCR,  or  nuclear  protein  extracts  were
examined by western blot analysis to detect HIF-1α protein.
Luciferase assays: HeLa cells were transfected with plasmids
pGL3-CHL-1 or pGL3-HRE [13] along with DM-HIF-1α,
using 6 µl Fugene 6 (Roche). Cells were transfected for 24 h,
medium replaced with fresh and incubated for a further 24 h.
Cells  transfected  with  DM-HIF-1α  were  incubated  in
normoxia, and cells transfected without DM-HIF-1α were
incubated  in  hypoxia.  Luciferase  gene  reporter  assay  was
performed  according  to  the  manufacturer’s  instructions
(Promega).
Analysis of chordin-like 1 and bone morphogenetic protein
−4  complex  formation:  Cos7  cells  were  transfected  as
described previously with either empty vector, pcDNA/V5-
HisC, or with the CHL-1 expression vector, pcDNA6 CHL-1/
V5-His. Cells were lysed, and whole cell extracts were made.
Next, 50 µl of extract was incubated with 250 ng rhBMP-4
(R&D  Systems,  Abingdon,  UK)  for  1  h  at  4  °C  before
incubation with 100 µl Ni-NTA magnetic beads, overnight at
4 °C with constant rocking. Ni-NTA magnetic beads had been
previously washed with binding buffer, pH 8.0, that contained
50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, and
0.05% Tween 20. Complexes were washed in wash buffer, pH
8.0, that contained 50 mM NaH2PO4, 300 mM NaCl, 20 mM
imidazole, and 0.05% Tween 20, and eluted off the magnetic
beads with elution buffer, pH 8.0, that contained 50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole, and 0.05%
Tween  20.  Samples  were  electrophoresed  on  SDS–PAGE
gels, transferred to PVDF membranes, and probed for either
V5-tagged CHL-1 or BMP-4.
Western blot analysis: Western blot analysis was performed
by  standard  procedures  [14].  HIF-1α  protein  levels  were
detected using a 1:500 dilution of either anti-HIF-1α (Biomol)
or  anti-HIF-1α  antibody  (AbCam,  Canbridge,  UK).  V5-
tagged CHL-1 was detected using a 1:5000 dilution of the anti-
V5 antibody (Invitrogen). BMP-2 and BMP-4 was detected
using  1:500  dilutions  of  the  anti-BMP-2  and  anti-BMP-4
antibodies  (R&D  Systems).  CHL-1  was  detected  using  a
1:1000 dilution of anti-CHL-1 antibody (R&D Systems).
Angiogenesis assay: Human umbilical vascular endothelial
cells and human diploid fibroblasts were obtained (day 1) as
cocultures in 24 well plates (AngioKit, TCS CellWorks Ltd.,
Buckingham, UK). Medium, with treatments or vehicle, was
replenished  on  days  1,  4,  7,  and  9.  Treatments  were
recombinant  human  BMP-2,  BMP-4,  and  CHL-1  (R&D
Systems). In addition, 2 ng/ml VEGF and 20 μM Suramin
(TCS Cellworks) were used as positive and negative controls
respectively. Tubule formation was examined at day 11. Cells
were  fixed  with  ice-cold  70%  ethanol  and  tubules  were
quantitated and visualized following fixing and staining for
CD31  platelet-endothelial  cell  adhesion  molecule  1
(PECAM-1) using a combined ELISA and histology kit (TCS
CellWorks  Ltd.,  UK)  according  to  the  manufacturer's
instructions.  Angiogenesis  was  quantitated  by  using  anti-
CD31 antibody coupled to a soluble substrate, ρ-nitrophenol
phosphate, which permits quantitation by an optical density
measurement. Plates were subsequently washed and stained
using  an  insoluble  substrate,  5-Bromo-4-chloro-3-indolyl
phosphate (BCIP)/Nitroblue tetrazolium (NBT), for tubule
visualization.
Statistical analysis: Each result was representative of at least
three independent experiments. All values are represented as
the mean ±standard error of measurement. The Student t-test
was used to determine statistical differences. Significance of
results was indicated when p<0.05.
RESULTS
Upregulation of chordin-like 1 in human retinal pericytes in
response to hypoxia: The transcriptomic response of human
retinal pericytes to hypoxia was examined. The mean signal–
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1140TABLE 2. DIFFERENTIAL GENE EXPRESSION IN HUMAN RETINAL PERICYTES EXPOSED TO HYPOXIA.
Number Accession number     Description SLR
Upregulated genes
1 NM_000076.1 cyclin-dependent kinase inhibitor 1C (p57, Kip2, CDKN1C) 1.7
2 NM_000963.1 prostaglandin-endoperoxide synthase 2 (prostaglandin GH synthase and
cyclooxygenase, PTGS2)
1.43
3 NM_013332.1 hypoxia-inducible protein 2 (HIG2) 1.43
4 BC005254.1 Similar to C-type (calcium dependent, carbohydrate-recognition domain)
lectin, superfamily member 2 (activation-induced), clone MGC:12289
1.4
5 NM_016109 PPAR(gamma) angiopoietin related protein (PGAR) 1.36
6 AF064238.3 smoothelin large isoform L2 (SMTN) 1.26
7 AF022375.1 vascular endothelial growth factor 1.26
8 NM_014883.1 KIAA0914 gene product (KIAA0914) 1.16
9 NM_015675.1 growth arrest and DNA-damage-inducible, beta (GADD45B) 1.13
10 NM_002166.1 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
(ID2)
1.06
11 NM_017606.1 hypothetical protein DKFZp434K1210 (DKFZp434K1210) 1.06
12 BC005127.1 adipose differentiation-related protein, clone MGC:10598 1.03
13 NM_020142.1 NADH:ubiquinone oxidoreductase MLRQ subunit homolog (LOC56901)1.03
14 NM_003734.2 amine oxidase, copper containing 3 (vascular adhesion protein 1, AOC3) 1
15 NM_006931.1 solute carrier family 2 (facilitated glucose transporter), member 3
(SLC2A3)
0.96
16 S73751.1 acyl CoA:cholesterol acyltransferase 0.93
17 AL048423.1 EST: integrin, beta 5 0.9
18 NM_003897.1 immediate early response 3 (IER3) 0.9
19 NM_005195.1 CCAATenhancer binding protein (CEBP), delta (CEBPD) 0.9
20 AL049176 DNA sequence from clone 141H5 on chromosome Xq22.1–23. Contains
parts of a novel Chordin LIKE protein with von Willebrand factor type C
domains.
0.9
21 NM_020639.1 ankyrin repeat domain 3 (ANKRD3) 0.9
22 NM_002912.1 REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta
(REV3L)
0.83
23 NM_000954.1 prostaglandin D2 synthase (21kD, brain; PTGDS) 0.83
24 BC000125.1 Similar to transforming growth factor, beta 1, clone MGC:3119 0.76
25 AI078167 EST: nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha
0.76
26 NM_005384.1 nuclear factor, interleukin 3 regulated (NFIL3) 0.76
27 NM_019058.1 hypothetical protein (FLJ20500), mRNA. RTP801 0.73
28 NM_003670.1 basic helix-loop-helix domain containing, class B, 2 (BHLHB2) 0.66
Downregulated genes
1 NM_000903.1 diaphorase (NADHNADPH, cytochrome b-5 reductase, DIA4) -2.16
2 NM_003234.1 transferrin receptor (p90, CD71, TFRC) -1.53
3 NM_020299.1 aldo-keto reductase family 1, member B10 (AKR1B10) -1.53
4 NM_018092.1 neuropilin (NRP) and tolloid (TLL)-like 2 (NETO2) -1.23
5 M21692.1 class I alcohol dehydrogenase (ADH2) beta-1 subunit -1
6 D45421.1 mRNA for phosphodiesterase I alpha -0.86
7 AK021882.1 cDNA FLJ11820 fis, clone HEMBA1006445, highly similar to putative
tumor supressor NOEY2
-0.76
The transcriptional response of human retinal pericytes to hypoxia was examined by microarray analysis, the SLR (signal-log
ratio) is the mean value of three independent experiments.
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Using  oxygen  quenching  oxymetry,  we  determined
extracellular oxygen tensions at the level of the monolayer.
Cells cultured in normoxia had a mean pO2 measurement of
140±2.79 mmHg, cells cultured in hypoxia had a mean pO2
measurement of 2.12±0.94 mmHg. The ambient pO2 in the
hypoxia chamber was 6.21±0.08 mmHg (data not shown).
CHL-1 (upregulated gene number 20) is a novel gene not
previously  associated  with  diabetic  retinopathy  [9,15,16].
CHL-1 was upregulated in pericytes by hypoxia with a mean
SLR of 0.9, corresponding to a 1.9 fold increase in expression
(p<0.001). Two genes previously known to be associated with
diabetic  retinopathy  were  also  upregulated:  VEGF
(upregulated  gene  number  7)  is  implicated  in  diabetic
retinopathy,  contributing  to  endothelial  proliferation,
permeability,  and  angiogenesis  [2],  and  is  known  to  be
upregulated in pericytes in response to hypoxia [17]. VEGF
was upregulated in pericytes by hypoxia with a mean SLR of
1.26,  corresponding  to  a  2.4  fold  increase  in  expression
(p<0.001),  and  Cox2  (upregulated  gene  number  2)  is
associated with neovascularisation in models of retinopathy
[18,19]. Cox2 was upregulated in pericytes by hypoxia with a
mean SLR of 1.43, corresponding to a 2.7 fold increase in
expression (p<0.05). To examine the upregulation of CHL-1
along  with  genes  known  to  be  upregulated  in  diabetic
retinopathy, we performed real-time quantitative PCR. As
determined by quantitative PCR over a time course (0, 6, 24
and 48 h) of exposure to hypoxia (1% O2), CHL-1 mRNA was
upregulated 1.7 fold by 48 h (p<0.05; Figure 1A), and VEGF
and Cox 2 mRNAs were upregulated twofold by 48 h (p<0.05;
Figure 1B,C).
Chordin-like  1  expression  is  directly  transactivated  by
hypoxia inducible factor-1α: The upstream region of CHL-1
was identified using the Human Genome Browser Gateway at
the  UCSC  interface.  A  1537  bp  fragment  of  the  CHL-1
promoter was cloned, sequenced and inserted into the reporter
vector  pGL3  Basic  (Promega),  and  named  pGL3  CHL-1.
Bioinformatic analysis of transcription factors binding to this
region of the promoter was performed using MatInspectorTM
software, and a putative HIF-1α binding site was located in
the proximal promoter (data not shown).
Human retinal pericytes were exposed to 1% O2 for 0, 6,
24, and 48 h. Nuclear and cytosolic extracts were prepared
and used for western blotting. HIF-1α protein expression was
dramatically  increased  by  6  h  of  hypoxia  and  remained
elevated by 48 h (Figure 2A).
To determine if the CHL-1 promoter with the putative
HIF-1α binding sequences was truly HIF-1α responsive, we
transfected WT and DM constructs expressing HIF-1α into
retinal pericytes. Semiquantitative RT–PCR was performed
on RNA isolated from these cells for genes known to be
HIF-1α  responsive,  VEGF  and  Cox2,  and  for  the  novel
hypoxia regulated gene CHL-1. In addition, 18S rRNA PCR
was performed as a loading control (Figure 2B). Expression
of the transiently transfected HIF-1α is also shown in Figure
2. The level of CHL-1 mRNA expression in these transiently
transfected cells was quantitated using real-time PCR (Figure
2C). Overexpression of HIF-1α was confirmed by western
blotting (Figure 2B).
To further determine the response of the CHL-1 promoter
to HIF-1α, we transfected HeLa cells with pGL3 CHL-1 and
either stimulated with 1% O2 or transfected with pGL3 CHL-1
and  DM-HIF-1α.  As  a  control,  the  experiment  was  also
Figure 1. Validation of three genes differentially expressed in human
retinal pericytes (hRPC) in response to hypoxia. The upregulation of
a selection of genes was validated with real time PCR, using a
PerkinElmer 7700 analyzer, on cDNA generated from human retinal
pericytes exposed to increasing periods of hypoxia (0, 6, 24, and 48
h). All results were normalized to 18S rRNA, using a pre-developed
assay  reagent.  Data  are  expressed  as  mean  relative  quantity  of
mRNA,  relative  to  control,  for  three  independent  experiments
±standard error of measurement for (A) CHL-1 mRNA, (B) VEGF
mRNA, and (C) Cox 2 mRNA. Data are expressed as mean±SEM
values. The asterisk indicates a significance at p<0.05 and the double
asterisk indicates a significance at p<0.001.
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performed using a promoter reporter construct containing fourFigure  2.  HIF-1α  drives  expression  of  chordin-like  1  in  retinal
pericytes exposed to hypoxia. A: western blot analysis of nuclear
extracts  generated  from  human  retinal  pericytes  exposed  to
increasing periods of hypoxia (0, 6, 24, and 48 h) for HIF-1α shows
upregulation of the protein by 6 h. B: Transfection of human retinal
pericytes maintained in normoxia with expression vectors for HIF-1
α, C is control/empty vector, WT is wild type vector, WT-HIF-1 α,
DM is double mutant vector, DM-HIF-1 α, using the transfection
reagent  Fugene6,  induces  expression  of  many  of  the  genes
upregulated in response to hypoxia, as measured by RT–PCR. 18S
PCR  is  shown  as  a  loading  control  and  western  blot  analysis
confirmed expression from each of the HIF-1α expressing plasmids.
C: Induction of CHL-1 mRNA in response to HIF-1α overexpression
was quantitated by real time PCR. CHL-1 levels were normalized to
18S rRNA, using a pre-developed assay reagent. Data are expressed
as mean relative quantity of mRNA, to control, for three independent
experiments ±standard error of measurement. D: HeLa cells were
transfected, using the transfection reagent Fugene6, with the CHL-1
promoter or a luciferase reporter construct containing four HIF-1α
responsive elements (HRE), alone (control), cotransfected with the
HIF-1α  expression  vector  DM-HIF-1α,  or  alone  and  subsequent
exposure to hypoxia for 24 h (1% O2). Cotransfection with DM-
HIF-1α as well as exposure to hypoxia induced activation of the
CHL-1 promoter and the HRE construct. Data are expressed as mean
±SEM values. The asterisk indicates a significance at p<0.05 and the
double asterisk indicates a significance at p<0.001.
hypoxia  responsive  elements  driving  the  luciferase  gene,
HRE-Luc, instead of pGL3 CHL-1. The CHL-1 promoter was
driven greater than threefold by HIF-1α (p<0.05) and greater
than  twofold  by  hypoxia  (p<0.05).  The  control  promoter
reporter construct, which contains four hypoxia responsive
elements (HREs) was driven greater than fourfold by HIF-1α
and greater than sixfold by hypoxia (both p<0.001; Figure
2D).
Chordin-like  1  expressed  in  human  retinal  pericytes  is
secreted and binds to bone morphogenetic protein-4: CHL-1
mRNA  was  expressed  in  response  to  hypoxia  in  retinal
pericytes  (Figure  1C).  The  protein  sequence  for  CHL-1
contained a signal peptide. Conditioned media (20 μl) from
retinal pericytes exposed to hypoxia was examined by western
blotting for secretion of CHL-1 using an anti-CHL-1 antibody
(R&D  Systems).  Secreted  CHL-1  was  detectable  in  the
conditioned  media  and  was  upregulated  by  hypoxia,
correlating with the mRNA data (Figure 3A). CHL-1 is a BMP
antagonist and previously shown to bind BMP-2 [20] and
BMP-4 [9]. We investigated the expression of both these
BMPs  in  retinal  pericytes  in  response  to  normoxia  and
hypoxia. Both were expressed at the mRNA level (Figure 3B)
and  were  secreted  into  the  culture  media  as  detected  by
western blotting (Figure 3C). Exposure to hypoxia had no
significant expression on either BMP-2 or BMP-4 expression.
The  open  reading  frame  of  CHL-1  was  cloned  and
sequenced, and inserted inframe with the COOH-terminal V5
6xHis  tag  in  the  expression  vector  pcDNA6/V5His,  and
named pcDNA6 CHL-1/V5His. Cos7 cells were transfected
with empty pcDNA6V5His (E), or with the expression vector
pcDNA6 CHL-1/V5His (CHL-1) expressing V5His tagged
CHL-1.  Whole  cell  extracts  were  examined  by  western
blotting for V5 tagged CHL-1 expression using an anti-V5
antibody (Invitrogen; Figure 3D) Whole cell extracts from
Cos7 cells transfected with empty pcDNA6/V5His (E), or
with the expression vector pcDNA6 CHL-1/V5His (CHL-1)
expressing V5His tagged CHL-1, were incubated with 250 ng
rhBMP-4 (R&D Systems) and 100 ml NiNTA magnetic beads
at 4 °C overnight with rotation. The interaction of the two
proteins was demonstrated by pulling down any complexes
formed with the tagged CHL-1 using NiNTA magnetic beads
(Qiagen) which bound the 6xHis tag on the expressed CHL-1.
Proteins bound in a complex to CHl-1 were washed with wash
buffer and then eluted using elution buffer. Western blotting
was used to identify eluted proteins. CHl-1 was detected using
anti-V5 antibody (Invitrogen), and BMP-4, using an anti-
BMP-4 antibody (R&D Systems). The complexes bound to
the  Ni-NTA  magnetic  beads  contained  both  CHL-1  and
BMP-4 (Figure 3E).
Bone morphogenetic protein-4 inhibits angiogenesis and is
antagonized by chordin-like 1: BMPs have been previously
reported to be negative growth regulators in the adult retinal
pigmented epithelium [21], and, more specifically, BMP-4
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1143has  been  demonstrated  to  mediate  apoptosis  of  capillary
endothelial cells [22]. We wanted to determine the angiogenic
effects of BMPs and CHL-1 using an in vitro angiogenesis
assay (AngioKit, TCS Cellworks). Using 2 ng/ml VEGF and
20  μM  Suramin  as  positive  and  negative  controls,
respectively,  we  successfully  stimulated  (p<0.001)  and
inhibited (p<0.001) angiogenesis (Figure 4A,D). While 10 ng/
ml BMP-2 appeared to negatively regulate angiogenesis, this
effect  was  not  significant;  however,  10  ng/ml  BMP-4
significantly inhibited angiogenesis (p=0.0015; Figure 5B,D).
Figure 3. Chordin-like 1 expressed in human retinal pericytes is
secreted and binds to bone morphogenetic protein-4. A: Conditioned
media from HRPC exposed to 1% O2 for 24 and 48 h was examined
by western blot analysis for secretion of CHL-1, using an anti-CHL-1
antibody. B and C: BMP-2 and BMP-4 expression in HRPC was
examined in cells cultured in normoxia (N) and hypoxia (H) by RT–
PCR  (B)  and  secreted  BMP2  and  BMP-4  were  detected  in
conditioned media from HRPC exposed to 1% O2 for 24 and 48 h (C).
D: Transfection of the expression vector pcDNA6/CHL-1 V5-His
into Cos7 cells, using the transfection reagent Fugene 6, resulted in
expression of an approximately 60 kDa protein, which was detectable
using an anti-V5 antibody. Cells were transfected with either an
empty  vector  (E),  pcDNA6/V5-His  C,  or  a  V5  tagged  CHL-1
expressing vector (CHL-1), pcDNA6/CHL-1 V5-His. E: Whole cell
extracts from Cos7 cells were transfected, using the transfection
reagent  Fugene  6,  with  empty  pcDNA6/V5His  (E),  or  with  the
expression  vector  pcDNA6  CHL-1/V5His  (CHL-1)  expressing
V5His tagged CHL-1, were incubated with 250 ng rhBMP-4 and 100
ml NiNTA magnetic beads at 4 °C overnight. The complexes were
washed, the beads and examined by western blotting for the presence
of CHL-1, using anti-V5 antibody, and BMP-4, using an anti-BMP-4
antibody.
CHL-1  alone  had  no  effect  on  angiogenesis;  however,  it
reversed the inhibitory effect of BMP-4 (Figure 4C,D).
Vascular endothelial growth factor and bone morphogenetic
protein-4 co-regulate angiogenesis: To examine whether the
pro- and anti-angiogenic effects of VEGF and BMP-4 were
mutually exclusive, we used these growth factors alone and
in combination in an angiogenesis assay. We found 2 ng/ml
VEGF stimulated angiogenesis and 10 ng/ml BMP-4 inhibited
angiogenesis. In combination the two growth factors have no
effect on angiogenesis (Figure 5).
DISCUSSION
The  pathologic  aberrations  associated  with  diabetic
retinopathy are localized primarily in the retinal capillaries.
Pericyte loss and microaneurysm formation are hallmarks of
early changes in the retinas of diabetic patients [23]. Retinal
pericytes  have  been  demonstrated  to  be  involved  in  the
regulation of endothelial cell number and morphology and
microvessel  architecture  [8].  We  have  investigated  the
transcriptomic response of human retinal pericytes to hypoxic
insult. Over three biologic replicate experiments, 35 genes (28
upregulated  and  seven  downregulated)  demonstrated
differential expression after 48 h exposure to hypoxia. Among
the  upregulated  genes  were  those  whose  expression  has
previously been associated with both hypoxia and diabetic
retinopathy, such as VEGF [24–27] and Cox2 [18,28]. One
gene, CHL-1/ventroptin has been described in the context of
the  developing  retina  [9];  however,  its  regulation  or  an
association with a disease process is yet to be described.
HIF-1α is a transcription factor implicated in hypoxia-
elicited  transcription.  It  binds  HRE,  a  consensus  element
within  promoters.  We  examined  the  promoters  of  the
upregulated genes for the presence of the HIF-1α binding site
(data not shown) and found 18 of the 27 upregulated genes
contained HIF binding elements, including CHL-1. We also
demonstrated increased nuclear presence of HIF-1α over a
timecourse  of  exposure  to  hypoxia.  Overexpression  of
HIF-1α drove the expression of many of the genes with HRE
binding sites within their promoters, such as VEGF, Cox2, and
CHL-1.
Our  data  demonstrate  that  CHL-1  (Ventroptin,
Neuralin-1),  a  BMP  antagonist,  is  expressed  by  retinal
pericytes in response to hypoxic insult. Its promoter contains
binding sites for many transcription factors, including the
known hypoxia responsive transcription factors HIF-1α and
cyclic AMP response element-binding protein (CREB; data
not  shown).  We  have  demonstrated  that  CHL-1  mRNA
expression and the CHL-1 promoter is driven by hypoxia and
by  overexpressing  HIF-1α.  This  suggests  that  HIF-1α
contributes  to  the  expression  of  CHL-1  in  a  hypoxic
environment.  Another  possible  regulator  of  CHL-1
expression may be VEGF, as VEGF mRNA is upregulated by
hypoxia by 6h, it is possible it contributes to the upregulation
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1144of  CHL-1  expression  by  24h,  as  activation  of  the  VEGF
receptors activates multiple signaling pathways [29]and the
precise  regulation  of  the  CHL-1  promoter  has  yet  to  be
defined.
CHL-1 is a secreted protein expressed in the developing
retina [9]. CHL-1 has three cysteine rich repeats (CRs). CRs
are characteristic motifs that are conserved in some proteins
including von Willebrand factor and chordin as well as other
extracellular  proteins,  of  which  several  are  involved  in
regulation of BMP signaling regulation [30]. Because the
three  CRs  of  CHL-1  were  significantly  homologous  to
Chordin, Sakuta et al. [9] hypothesized and demonstrated that
ventroptin (CHL-1) binds to and inhibits BMP-4. Another
study demonstrated that ventroptin also inhibits BMP-2 [20].
This adds CHL-1 to a growing family of secretory proteins
that antagonize BMPs, including chordin, Noggin, Cerberus,
DAN, and Gremlin [31–34]. We have previously shown the
BMP  antagonist  Gremlin  to  be  upregulated  in  diabetic
nephropathy [35,36] and localized to the outer retina of STZ
diabetic  mice  [37].  Both  BMP-2  and  BMP-4  have  been
previously demonstrated to act as negative growth regulators
in the retinal pigmented epithelium (RPE) [21]. We have
found that human retinal pericytes express both BMP-2 and
BMP-4. Other reports have shown decreases in BMP-4 in the
retina in response to hypoxia [21]; however, in our study
BMP-4 mRNA levels in retinal pericytes were unaffected by
hypoxia. BMP-4 itself has been shown to promote apoptosis
in the developing retina [38] and play a role in capillary
apoptosis  [22].  BMPs  have  also  been  demonstrated  to
stimulate angiogenesis through the production of VEGF [10,
39]. We have shown that retinal pericytes not only express and
secrete both BMP-2 and BMP-4, but they also secrete CHL-1
Figure 4. Chordin-like 1 modulates the
antiangiogenic  effect  of  bone
morphogenetic  protein-4.  Human
umbilical  vascular  endothelial
cells(HUVECs)  and  human  diploid
fibroblasts  were  obtained  (day  1)  as
cocultures in 24 well plates. Medium,
with  treatments  or  vehicle,  was
replenished on days 1, 4, 7, and 9. The
assay was treated with VEGF, Suramin,
recombinant  human  BMP-2,  BMP-4,
and  CHL-1.  Tubule  formation  was
examined at day 11. Cells were fixed,
quantitated,  and  visualized  using  a
combined ELISA and histology kit. A:
VEGF (2 ng/ml) and Suramin (20 mM)
were  used  as  positive  and  negative
angiogenesis controls, respectively. B:
Cells were treated with rhBMP-2 and
rhBMP-4.  BMP-4  significantly
inhibited angiogenesis at 10 ng/ml. C:
CHL-1 inhibited BMP-4; CHL-1 alone
had  no  significant  effect  on
angiogenesis,  however  it  inhibited
BMP-4s  anti-angiogenic  effects.
Images A-C are shown at magnification
10X. Representative images are shown
in  A-C.  D:  Angiogenesis  was
quantitated  by  using  anti-CD31
antibody coupled to a soluble substrate,
ρ-nitrophenol  phosphate  (ρ-NPP),
which permits quantitation by an optical
density  measurement.  The  asterisk
indicates a significance at p<0.05 and
the  double  asterisk  indicates  a
significance at p<0.001.
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1145in  response  to  hypoxic  stimulus.  Hypoxia  is  a  well
documented  stimulus  for  angiogenesis  and  retinal
neovascularization [40,41]. We have demonstrated here that
hypoxia-induced HIF-1α drives CHL-1 expression in retinal
pericytes, and that expressed recombinant V5-tagged CHL-1
binds BMP-4. Binding of CHL-1 to members of the BMP
family has been previously demonstrated to modulate the
function of the BMP [9]. Two studies showed regulation of
angiogenesis by BMPs via VEGF [10,39]. More recently Vogt
et al. [42] demonstrated that stimulation of ARPE-19 cells
with BMP-4 results in increased VEGF expression. It has been
documented that VEGFs secreted by epithelia, including the
RPE,  are  likely  to  mediate  paracrine  vascular  signals  for
adjacent endothelial (discussed in [43]). BMP-4 expression in
the retina may have different effects on different cell types,
such as increased VEGF expression from RPE cells and an
anti-angiogenic effect on endothelial cells. In this study we
demonstrated direct modulation of angiogenesis by BMP-4 in
an  in  vitro  angiogenesis  assay  and  that  this  inhibition  is
modulated  by  the  addition  of  CHL-1.  We  have  also
demonstrated that CHL-1 binds to BMP-4 and suggest that
this  binding  prevents  BMP-4  from  acting  at  its  receptor.
Therefore, BMP-4 may play a role in the retina in maintaining
capillary  endothelial  cell  number,  and  the  modulation  of
endogenous BMP levels in the retina may play a role in the
plasticity of the retinal microvasculature in disease states.
Induction of a BMP antagonist, namely CHL-1, by ischemic
insult in a pathologic setting may function to neutralize BMP
action on endothelial cells. Specifically, modulation of local
BMP-4 activity in maintenance of capillary cell number by
CHL-1, in response to a hypoxic environment, may contribute
to  retinal  neovascularization,  by  allowing  proliferation  of
endothelial cells. Gariano and Gardner [44] recently reviewed
retinal angiogenesis and affirmed that pathological retinal
Figure 5. Vascular endothelial growth
factor  and  bone  morphogenetic
protein-4  co-regulate  angiogenesis.
Human umbilical vascular endothelial
cells  (HUVECs)  and  human  diploid
fibroblasts  were  obtained  (day  1)  as
cocultures in 24 well plates. Medium,
with  treatments  or  vehicle,  was
replenished on days 1, 4, 7, and 9. The
assay  was  treated  with  vascular
endothelial  growth  factor  (VEGF),
Suramin,  and  recombinant  human
BMP-4.  Tubule  formation  was
examined at day 11. Cells were fixed,
quantitated,  and  visualized  using  a
combined ELISA and histology kit. A:
Angiogenesis assay demonstrating the
combined  effects  of  VEGF  (pro-
angiogenic)  and  BMP-4  (anti-
angiogenic) on angiogenesis. Suramin
was  used  as  a  negative  control.
(magnification  10X).  Representative
images are shown. B: Angiogenesis was
quantitated  by  using  anti-CD31
antibody coupled to a soluble substrate,
ρ-nitrophenol  phosphate  (ρ-NPP),
which permits quantitation by an optical
density  measurement.  Data  are
expressed  as  mean±SEM  values.  The
asterisk  indicates  a  significance  at
p<0.01 and the double asterisk indicates
a significance at p<0.001.
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1146neovascularization  in  the  diabetic  retina  results  from  an
imbalance of pro-angiogenic and anti-angiogenic factors. We
have demonstrated in this study that angiogenic homeostasis
may be maintained by such a combination, namely VEGF and
BMP-4. We suggest that the balance between BMP-4 and
VEGF is crucial in maintaining angiogenic homeostasis, and
that the inhibition of the anti-angiogenic factor, BMP-4, by
CHL-1, along with increases in VEGF tilt the balance in favor
of a pro-angiogenic retinal environment.
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